Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900–1.
CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.
Heier JS, Brown DM, Chong V. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.
Regatieri CV, Branchini L, Duker JS. The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2011;42[Suppl]:S56–66.
Fang PP, Domdei N, Herrmann P, et al. Minimal optical coherence tomography B-scan density for reliable detection of intraretinal and subretinal fluid in macular diseases. Retina. 2019;39:150–6.
Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146:496–500.
Branchini L, Regatieri C, Adhi M, et al. Effect of intravitreous antivascular endothelial growth factor therapy on choroidal thickness in neovascular age-related macular degeneration using spectral-domain optical coherence tomography. JAMA Ophthalmol. 2013;131:693–4.
Mazaraki K, Fassnacht-Riedele H, Blum R, Becker M, Michels S. Change in choroidal thickness after intravitreal aflibercept in pretreated and treatmentnaive eyes for neovascular age-related macular degeneration. Br J Ophthalmol. 2016;99:1341–4.
McDonnell EC, Heussen FM, Ruiz-Garcia H, et al. Effect of anti-VEGF treatment on choroidal thickness over time in patients with neovascular age related macular degeneration. Eur J Ophthalmol. 2014;24:897–903.
Framme C, Panagakis G, Birngruber R. Effects on choroidal neovascularization after anti-VEGF upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Investig Ophthalmol Vis Sci. 2010;51:1671–6.
Ünlü C, Erdogan G, Gunay BO, Kardes E, Akcay BI, Ergin A. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema. Int Ophthalmol. 2017;37:147–58.
Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2009;223:370–5.
Spooner K, Hong T, Nair R, et al. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol. 2019;97:e706–12.
Savastano MC, Lumbroso B, Rispoli M. In vivo characterization of retinal vascularization morphology using optical coherence tomography angiography. Retina. 2015;35:2196–203.
Spaide RF. Choriocapillaris flow features follow a power law distribution: implications for characterization and mechanisms of disease progression. Am J Ophthalmol. 2016;170:58–67.
Coscas F, Lupidi M, Boulet JF, et al. Optical coherence tomography angiography in exudative age-related macular degeneration: a predictive model for treatment decisions. Br J Ophthalmol. 2018;103:1342–6.
Pilotto E, Frizziero L, Daniele AR, et al. Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGF. Br J Ophthalmol. 2019;103:67–71.
Abri Aghdam K, Seidensticker F, Pielen A, Framme C, Junker B. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography. Lasers Surg Med. 2016;48:668–77.
Kniestedt C, Stamper RL. Visual acuity and its measurement. Ophthalmol Clin N Am. 2003;16:155–70.
Coscas F, Puche N, Coscas G, et al. Comparison of macular choroidal thickness in adult onset foveomacular vitelliform dystrophy and age-related macular degeneration. Investig Ophthalmol Vis Sci. 2014;55:64–9.
Jia Y, Tan O, Tokayer J, Subhash H, Fujimoto JG, Hornegger J, Huang D, et al. Split spectrum amplitude-decorrelation angiography with optical coherence tomography. Opt Express. 2012;20:4710–25.
Huang D, Jia Y, Gao SS, Lumbroso B, Rispoli M. Optical coherence tomography angiography using the optovue device. Dev Ophthalmol. 2016;56:6–12.
Razavi S, Souied EH, Darvizeh F, Querques G. Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol. 2015;160:1006–13.
Palkovits S, Seidel G, Pertl L, et al. Macular choroidal volume changes after intravitreal Bevacizumab for exudative age-related macular degeneration. Retina. 2017;37:2262–8.
Amarakoon S, Martinez-Ciriano JP, van den Born LI, Baarsma S, Missotten T. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks. Acta Ophthalmol. 2019;97:107–12.
Sizmaz S, Kucukerdonmez C, Kal A, Pinarci EY, Canan H, Yilmaz G. Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab. Eur J Ophthalmol. 2014;24:904–10.
Ghassemifar R, Lai CM, Rakoczy PE. VEGF differentially regulates transcription and translation of ZO-1alpha + and ZO-1alpha- and mediates trans-epithelial resistance in cultured endothelial and epithelial cells. Cell Tissue Res. 2006;323:117–25.
Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retinal Eye Res. 2013;34:19–48.
Terasaki H, Sakamoto T, Shirasawa M, et al. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro. Retina. 2015;35:1007–15.
Kaur C, Foulds WS, Ling EA. Blood–retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retinal Eye Res. 2008;27:622–47.
Fontaine O, Olivier S, Descovich D, Cordahi G, Vaucher E, Lesk MR. The effect of intravitreal injection of bevacizumab on retinal circulation in patients with neovascular macular degeneration. Investig Ophthalmol Vis Sci. 2011;52:7400–5.
Barak A, Burgansky-Eliash Z, Barash H, Nelson DA, Grinvald A, Loewenstein A. The effect of intravitreal bevacizumab (Avastin) injection on retinal blood flow velocity in patients with choroidal neovascularization. Eur J Ophthalmol. 2012;22:423–30.
Micieli JA, Tsui E, Lam WC, Brent MH, Devenyi RG, Hudson C. Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration. Acta Ophthalmol. 2012;90:e13–20.
Mottet B, Aptel F, Geiser MH, et al. Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age-related macular degeneration patients. Acta Ophthalmol. 2018;96:e783–8.
Segal O, Barayev E, Nemet AY, Mimouni M. Predicting response of exudative age-related macular degeneration to Bevacizumab based on spectralis optical coherence tomography. Retina. 2016;36:259–63.
Mathew R, Richardson M, Sivaprasad S. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. Am J Ophthalmol. 2013;155:720–6.
Gamulescu MA, Panagakis G, Theek C, Helbig H. Predictive factors in OCT analysis for visual outcome in exudative AMD. J Ophthalmol. 2012:851648.